Patents by Inventor Yoshiharu Hiramatsu
Yoshiharu Hiramatsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170298058Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect, e.g. a compound of Formula (I): wherein R2 is a hydrogen atom or the like; ring A is five- to seven-cycloalkane or the like; C is a carbon atom; Q1 and Q2 are carbon atoms or the like; R9a and R9b are carbon atoms or the like; R6 is cycloalkyl or the like; R7 is a group represented by the formula: wherein ring D is benzene or the like; carbon atom a and b are carbon atoms; ring B is an aromatic carbocyclic ring or the like; s and s? are 0 or the like; R9 and R9? are halogen or the like, or the like, or its pharmaceutically acceptable salt.Type: ApplicationFiled: December 7, 2016Publication date: October 19, 2017Inventors: Hiroyuki KAI, Satoru TANAKA, Yoshiharu HIRAMATSU, Azusa NOZU, Ken'ichioh NAKAMAURA
-
Patent number: 9550763Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect, e.g. a compound of Formula (I): wherein R2 is a hydrogen atom or the like; ring A is five- to seven-cycloalkane or the like; C is a carbon atom; Q1 and Q2 are carbon atoms or the like; R9a and R9b are carbon atoms or the like; R6 is cycloalkyl or the like; R7 is a group represented by the formula: wherein ring D is benzene or the like; carbon atom a and b are carbon atoms; ring B is an aromatic carbocyclic ring or the like; s and s? are 0 or the like; R9 and R9? are halogen or the like, or the like, or its pharmaceutically acceptable salt.Type: GrantFiled: February 8, 2013Date of Patent: January 24, 2017Assignee: SHIONOGI & CO., LTD.Inventors: Hiroyuki Kai, Satoru Tanaka, Yoshiharu Hiramatsu, Azusa Nozu, Ken'ichioh Nakamura
-
Publication number: 20160024072Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect, e.g. a compound of Formula (I): wherein R2 is a hydrogen atom or the like; ring A is five- to seven-cycloalkane or the like; C is a carbon atom; Q1 and Q2 are carbon atoms or the like; R9a and R9b are carbon atoms or the like; R6 is cycloalkyl or the like; R7 is a group represented by the formula: wherein ring D is benzene or the like; carbon atom a and b are carbon atoms; ring B is an aromatic carbocyclic ring or the like; s and s? are 0 or the like; R9 and R9? are halogen or the like, or the like, or its pharmaceutically acceptable salt.Type: ApplicationFiled: February 8, 2013Publication date: January 28, 2016Inventors: Hiroyuki KAI, Satoru TANAKA, Yoshiharu HIRAMATSU, Azusa NOZU, Ken'ichioh NAKAMURA
-
Patent number: 8367666Abstract: The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R1, R2, R3, R4, and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.Type: GrantFiled: February 28, 2012Date of Patent: February 5, 2013Assignee: Shionogi & Co., Ltd.Inventors: Takashi Sasatani, Yoshiharu Hiramatsu, Susumu Mitsumori
-
Publication number: 20120208813Abstract: The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R1, R2, R3, R4, and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.Type: ApplicationFiled: February 28, 2012Publication date: August 16, 2012Inventors: Natsuki ISHIZUKA, Takashi SASATANI, Yoshiharu HIRAMATSU, Masanao INAGAKI, Masahide ODAN, Hiroshi HASHIZUMI, Susumu MITSUMORI, Yasuhiko FUJII, Yoshikazu FUKUI, Hideaki WATANABE, Jun SATO
-
Patent number: 8178681Abstract: The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R1 is optionally substituted C1-C8 alkyl and the like; R2 is C1-C6 alkyl; R3 is C1-C6 alkyl and the like; or R2 and R3 taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R4 is hydrogen and the like; G is a group selected from the groups shown by the formula an the like: wherein R5 is hydrogen and the like; X1 is a single bond and the like; X2 is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R6)—, wherein R6 is hydrogen and the like, and the like; X3 is a single bond and the like; a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredieType: GrantFiled: October 28, 2005Date of Patent: May 15, 2012Assignee: Shionogi & Co., Ltd.Inventors: Natsuki Ishizuka, Yoshiharu Hiramatsu, Yasuhiko Fujii, Yoshikazu Fukui
-
Patent number: 7956082Abstract: The present invention creates an indole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the generic formula (I) wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; R1, R2, R3, R4 and R5 are independently a hydrogen atom or a halogen atom etc.; R6 is C2-C4 alkyloxy etc.; R7 is independently a halogen atom etc.; R8 is independently C1-C4 alkyl etc.; R9 is carboxy etc.; Y is a single bond etc.; M is sulfonyl etc.; L1, L2 and L3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.Type: GrantFiled: July 20, 2006Date of Patent: June 7, 2011Assignee: Shionogi & Co., LtdInventors: Akira Kugimiya, Michitaka Shichijo, Yoshiharu Hiramatsu, Natsuki Ishizuka
-
Publication number: 20090258922Abstract: A compound having CRTH2 receptor antagonism, represented by the following formula (I). The compound is useful for the treatment of allergic diseases having a relation to eosinophils and the like. A compound of the formula (I): wherein a group represented by the formula: is a group represented by the formula: and the like, R1 is carboxy and the like, R3 is —(CH2)n-N(—Y)—SO2—Ar and the like, the other symbols are as defined in claim 1.Type: ApplicationFiled: March 27, 2009Publication date: October 15, 2009Inventors: Norihiko Tanimoto, Yoshiharu Hiramatsu, Susumu Mitsumori, Masanao Inagaki
-
Patent number: 7534897Abstract: A compound having CRTH2 receptor antagonism, represented by the following formula (I). The compound is useful for the treatment of allergic diseases having a relation to eosinophils and the like. A compound of the formula (I): wherein a group represented by the formula: is a group represented by the formula: and the like, R1 is carboxy and the like, R3 is —(CH2)n-N(—Y)—SO2—Ar and the like, the other symbols are as defined in claim 1.Type: GrantFiled: May 15, 2003Date of Patent: May 19, 2009Assignee: Shionogi & Co., Ltd.Inventors: Norihiko Tanimoto, Yoshiharu Hiramatsu, Susumu Mitsumori, Masanao Inagaki
-
Publication number: 20090030014Abstract: The present invention creates an indole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the generic formula (I) wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; R1, R2, R3, R4 and R5 are independently a hydrogen atom or a halogen atom etc.; R6 is C2-C4 alkyloxy etc.; R7 is independently a halogen atom etc.; R8 is independently C1-C4 alkyl etc.; R9 is carboxy etc.; Y is a single bond etc.; M is sulfonyl etc.; L1, L2 and L3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.Type: ApplicationFiled: July 20, 2006Publication date: January 29, 2009Inventors: Akira Kugimiya, Michitaka Shichijo, Yoshiharu Hiramatsu, Natsuki Ishizuka
-
Publication number: 20080103139Abstract: The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R1 is optionally substituted C1-C8 alkyl and the like; R2 is C1-C6 alkyl; R3 is C1-C6 alkyl and the like; or R2 and R3 taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R4 is hydrogen and the like; G is a group selected from the groups shown by the formula an the like: wherein R5 is hydrogen and the like; X1 is a single bond and the like; X2 is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R6)—, wherein R6 is hydrogen and the like, and the like; X3 is a single bond and the like; a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredienType: ApplicationFiled: October 28, 2005Publication date: May 1, 2008Inventors: Natsuki Ishizuka, Takashi Sasatani, Yoshiharu Hiramatsu, Masanao Inagaki, Masahide Odan, Hiroshi Hashizume, Susumu Mitsumori, Yasuhiko Fujii, Yoshikazu Fukui, Hideaki Watanabe, Jun Sato
-
Patent number: 7214832Abstract: The present invention provides a process for the preparation of a bicyclic aminoalcohol which comprises reacting a starting compound, nopinone (I), with XCH2COOR1 wherein X is halogen, and R1 is alkyl, in the presence of an additive and a base to produce a compound (II), converting it to oxime derivative (III), and reducing it with an aluminum hydrideType: GrantFiled: February 25, 2004Date of Patent: May 8, 2007Assignee: Shionogi & Co., Ltd.Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu, Susumu Mitsumori
-
Patent number: 7105564Abstract: The present invention provides novel compounds having a dual antagonistic activity against thromboxane A2 receptor and prostaglandin D2 receptor and pharmaceutical compositions comprising them. A compound of the formula (I): wherein R1 is —CH2—CH?CH—CH2—CH2—CH2—COOR2 or —CH?CH—CH2—CH2—CH2—COOR2; R2 is hydrogen or alkyl; m is 0 or 1; p is 0 or 1; X1 and X3 each is independently optionally substituted aryl or optionally substituted heteroaryl; X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or the like; X4 is —CH2—, —CH2—CH2—, —C(?O)—, or the like, have a dual antagonistic activity against both a thromboxane A2 receptor and a prostaglandin D2 receptor.Type: GrantFiled: March 2, 2000Date of Patent: September 12, 2006Assignee: Shionogi & Co., Ltd.Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu, Akinori Arimura
-
Patent number: 6933317Abstract: Compounds of the general formula (I) which are metabolically stable and have an antagonistic activity against PGD2 receptor: ? wherein Y is bicyclic ring; R1 is optionally substituted heteroaryl; R2 is hydrogen, etc.; R3 is —CH2—CH2—CH2—CH2—CH?CH—COOR4, —CH2—CH2—CH2—CH2—X1—CH2—COOR4, —CH2—CH?CH—CH2—X1—CH2—COOR4 or —CH2—CH2—CH2—COOR4; R4 is hydrogen, etc.; X1 is —O—, etc.Type: GrantFiled: October 26, 2001Date of Patent: August 23, 2005Assignee: Shionogi & Co. Ltd.Inventors: Norihiko Tanimoto, Yoshiharu Hiramatsu, Tsunetoshi Honma, Masanao Inagaki
-
Publication number: 20050171143Abstract: A compound having CRTH2 receptor antagonism, represented by the following formula (I). The compound is useful for the treatment of allergic diseases having a relation to eosinophils and the like. A compound of the formula (I): wherein a group represented by the formula: is a group represented by the formula: and the like, R1 is carboxy and the like, R3 is —(CH2)n-N(—Y)—SO2-Ar and the like, the other symbols are as defined in claim 1.Type: ApplicationFiled: May 15, 2003Publication date: August 4, 2005Inventors: Norihiko Tanimoto, Yoshiharu Hiramatsu, Susumu Mitsumori, Masanao Inagaki
-
Publication number: 20040171882Abstract: The present invention provides a process for the preparation of a bicyclic aminoalcohol which comprises reacting a starting compound, nopinone (I), with XCH2COOR1 wherein X is halogen, and R1 is alkyl, in the presence of an additive and a base to produce a compound (II), converting it to oxime derivative (III), and reducing it with an aluminum hydride.Type: ApplicationFiled: February 25, 2004Publication date: September 2, 2004Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu, Susumu Mitsumori
-
Publication number: 20040054003Abstract: Compounds of the general formula (I) which are metabolically stable and have an antagonistic activity against PGD2 receptor: 1Type: ApplicationFiled: April 18, 2003Publication date: March 18, 2004Inventors: Norihiko Tanimoto, Yoshiharu Hiramatsu, Tsunetoshi Honma
-
Patent number: 6495702Abstract: Processes for producing benzothiophenecarboxylic acid derivatives of the formula (I), which are useful as starting materials for producing drugs, are disclosed. Also disclosed is a process for preparing 5-hydroxybenzo[b]-thiophene-3-carboxylic acid derivatives of the formula (VI), which are specific PGD2 antagonists.Type: GrantFiled: September 26, 2001Date of Patent: December 17, 2002Assignee: Shionogi & Co., Ltd.Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu
-
Publication number: 20020161242Abstract: A process for preparing a compound having PGD2 antagonism represented by the formula (I), or a pharmaceutically acceptable salt or hydrate thereof, which process comprises reacting an amino alcohol of the formula (II) or its salt with a compound of the formula (III) or its reactive derivative, oxidizing the product with halo oxoacid in the presence of 2,2,6,6-tetramethylpiperidine-1-oxyls, reacting the product with an ylide under the conditions for Wittig reaction, and optionally deprotecting the product.Type: ApplicationFiled: April 29, 2002Publication date: October 31, 2002Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu
-
Patent number: 6465662Abstract: A process for preparing a compound having PGD2 antagonism represented by the formula (I), or a pharmaceutically acceptable salt or hydrate thereof, which process comprises reacting an amino alcohol of the formula (II) or its salt with a compound of the formula (III) or its reactive derivative, oxidizing the product with halo oxoacid in the presence of 2,2,6,6-tetramethylpiperidine-1-oxyls, reacting the product with an ylide under the conditions for Wittig reaction, and optionally deprotecting the product.Type: GrantFiled: April 29, 2002Date of Patent: October 15, 2002Assignee: Shionogi & Co., Ltd.Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu